Novel Self-nanomicellizing Solid Dispersion Based on Rebaudioside A: a Potential Nanoplatform for Oral Delivery of Curcumin
Overview
Affiliations
Purpose: Rebaudioside A (RA) has nanocarrier characteristics that allow it to self-assemble into micelles in aqueous solutions. The purpose of this study was to determine if a self-nanomicellizing solid dispersion based on RA could be utilized as an oral nano-drug delivery system.
Materials And Methods: Curcumin (Cur) served as a model hydrophobic drug, and a Cur-loaded self-nanomicellizing solid dispersion based on RA (RA-Cur) was formulated. The properties of RA-Cur in the solid state and in aqueous solution were characterized. The antioxidant activity and mechanism of RA-Cur endocytosis were also investigated. The pharmacokinetics, biodistribution in the intestinal tract, and anti-inflammation properties were also evaluated in vivo.
Results: RA-Cur could be easily fabricated, and it self-assembled into ultrasmall micelles (particle size ~4 nm) in a homogeneous distribution state (polydispersity index <0.2) when dissolved in water. Cur was readily encapsulated into RA micelles and this improved its water solubility (to 14.34±1.66 mg/mL), as well as its in vitro release and membrane permeability. The antioxidant activities of Cur in RA-Cur were also significantly improved. Biodistribution in the intestinal tract confirmed a significant enhancement of Cur absorption in the duodenum, jejunum, and ileum by encapsulation in RA-Cur, and the absorption of RA-Cur was governed by mixed transcytosis mechanisms. Pharmacokinetic tests of RA-Cur in rats revealed a dramatic 19.06-fold enhancement of oral bioavailability when compared to free Cur. More importantly, oral administration of RA-Cur could efficiently ameliorate ulcerative colitis in a mouse model induced by dextran sodium sulfate.
Conclusion: Self-nanomicellizing solid dispersions based on RA have great potential as novel oral nano-drug delivery systems for hydrophobic drugs such as Cur.
Fu H, Zheng X, Xu K, Zhang Y, Wu M, Xu M BMC Gastroenterol. 2024; 24(1):223.
PMID: 38992591 PMC: 11241987. DOI: 10.1186/s12876-024-03313-9.
Wang X, Wang Y, Tang T, Zhao G, Dong W, Li Q Pharmaceutics. 2023; 15(12).
PMID: 38140051 PMC: 10747166. DOI: 10.3390/pharmaceutics15122710.
Steviol glycosides as an alternative osmotic agent for peritoneal dialysis fluid.
Kopytina V, Pascual-Anton L, Toggweiler N, Arriero-Pais E, Strahl L, Albar-Vizcaino P Front Pharmacol. 2022; 13:868374.
PMID: 36052133 PMC: 9424724. DOI: 10.3389/fphar.2022.868374.
Goo Y, Sa C, Choi J, Kim M, Kim C, Kim H Int J Nanomedicine. 2021; 16:1245-1259.
PMID: 33633449 PMC: 7901570. DOI: 10.2147/IJN.S298450.
Obstacles against the Marketing of Curcumin as a Drug.
Hassanzadeh K, Buccarello L, Dragotto J, Mohammadi A, Corbo M, Feligioni M Int J Mol Sci. 2020; 21(18).
PMID: 32927725 PMC: 7554750. DOI: 10.3390/ijms21186619.